It was reported yesterday that the US Food and Drug Administration (USFDA) has approved United States-based Merck's Keytruda (pembrolizumab) plus Japan-based Eisai's Lenvima (lenvatinib) intended to treat patients with certain types of endometrial carcinoma.
Keytruda is a humanised monoclonal antibody, which blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, and is likely to affect both tumour cells and healthy cells, while Lenvima is a kinase inhibitor, which blocks the kinase activities of vascular endothelial growth factor receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Study patients had been treated with Keytruda 200mg intravenously every three weeks in combination with Lenvima 20mg once daily.
The products' approval was based on data from KEYNOTE-146/Study 111, a phase two, multi-cohort, multicentre, open-label and single-arm trial that recruited 108 patients with metastatic endometrial carcinoma.
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD